Johnson and Johnson’s Vision Care unit has received FDA approval for its Acuvue Theravision with Ketotifen, a drug-eluting contact lens that could make eyedrops obsolete for contact lens wearers suffering from allergic eye itch. The lens contains 19 mcg of ketotifen, an antihistamine, and has been shown to reduce itchy allergy eyes as quickly as three minutes after lens insertion and lasting up to 12 hours. The product was greenlit for use by the Japanese Ministry of Health almost a year ago. Companies have spent 60 years trying to develop medication-releasing contact lenses and many have failed, but Johnson and Johnson’s breakthrough is a result of a strong collaboration between J&J Vision Care, Janssen, and other strategic partners.

Categorized in: